$7.30
0.55% yesterday
Nasdaq, Sep 26, 10:00 pm CET
ISIN
US92764N1028
Symbol
VIR

Vir Biotechnology Inc Stock price

$7.30
-1.32 15.31% 1M
-2.67 26.78% 6M
-2.76 27.44% YTD
-1.95 21.08% 1Y
-37.74 83.79% 3Y
+3.61 97.83% 5Y
+3.61 97.83% 10Y
Nasdaq, Closing price Thu, Sep 26 2024
+0.04 0.55%
ISIN
US92764N1028
Symbol
VIR
Sector
Industry

Key metrics

Market capitalization $997.47m
Enterprise Value $-53.03m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 0.12
EV/Sales (TTM) EV/Sales -0.67
P/S ratio (TTM) P/S ratio 12.65
P/B ratio (TTM) P/B ratio 0.70
Revenue growth (TTM) Revenue growth -83.93%
Revenue (TTM) Revenue $78.88m
EBIT (operating result TTM) EBIT $-511.65m
Free Cash Flow (TTM) Free Cash Flow $-458.78m
Cash position $1.17b
EPS (TTM) EPS $-3.58
P/E forward negative
P/S forward 13.95
EV/Sales forward negative
Short interest 7.05%
Show more

Is Vir Biotechnology Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,900 stocks worldwide.

Vir Biotechnology Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

9 Analysts have issued a Vir Biotechnology Inc forecast:

6x Buy
67%
3x Hold
33%

Analyst Opinions

9 Analysts have issued a Vir Biotechnology Inc forecast:

Buy
67%
Hold
33%

Financial data from Vir Biotechnology Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '24
+/-
%
79 79
84% 84%
100%
- Direct Costs 21 21
58% 58%
26%
58 58
87% 87%
74%
- Selling and Administrative Expenses 125 125
16% 16%
159%
- Research and Development Expense 425 425
24% 24%
539%
-492 -492
83% 83%
-624%
- Depreciation and Amortization 20 20
14% 14%
25%
EBIT (Operating Income) EBIT -512 -512
76% 76%
-649%
Net Profit -483 -483
84% 84%
-612%

In millions USD.

Don't miss a Thing! We will send you all news about Vir Biotechnology Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Vir Biotechnology Inc Stock News

Neutral
Business Wire
17 days ago
SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that the exclusive worldwide license agreement with Sanofi announced on August 1, 2024, has closed following expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976. The agreement provides Vir with an exclusive worldwide license to three clinical-stage masked T-cell enga...
Neutral
24/7 Wall Street
about 2 months ago
24/7 Wall St. Insights Market pullbacks can make nervous investors leery of investing in industries that are speculative in nature.
Neutral
Seeking Alpha
about 2 months ago
Vir Biotechnology, Inc. (NASDAQ:VIR ) Q2 2024 Earnings Conference Call August 1, 2024 4:30 PM ET Company Participants Richard Lepke - Senior Director, Investor Relations Marianne De Backer - Chief Executive Officer Jennifer Towne - Executive Vice President and Chief Scientific Officer Mark Eisner - Executive Vice President and Chief Medical Officer Brent Sabatini - Chief Accounting Officer Conf...
More Vir Biotechnology Inc News

Company Profile

Vir Biotechnology, Inc. operates as a clinical-stage immunology company that focuses on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. The firm's technology platforms include antibody, T cell, innate immunity and siRNA, which are designed to stimulate and enhance the immune system by exploiting critical observations of natural immune processes. The company was founded by Robert Taylor Nelsen, Klaus Frueh, Jay Parrish, Lawrence Corey, and Louis Picker in April 7, 2016 and is headquartered in San Francisco, CA.

Head office United States
CEO Marianne Backer
Employees 587
Founded 2016
Website www.vir.bio

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today